Impact of Systemic Autoimmune Diseases on Treatment Outcomes and Radiation Toxicities in Patients with Stage I Non-Small Cell Lung Cancer Receiving Stereotactic Body Radiation Therapy: A Matched Case-Control Analysis.
lung cancer
prognosis prediction
radiation pneumonitis
stereotactic body radiation therapy
systemic autoimmune disease
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Nov 2022
30 Nov 2022
Historique:
received:
12
10
2022
revised:
26
11
2022
accepted:
28
11
2022
entrez:
11
12
2022
pubmed:
12
12
2022
medline:
12
12
2022
Statut:
epublish
Résumé
We aimed to evaluate the impact of systemic autoimmune diseases (SADs) on treatment outcomes and radiation toxicities following stereotactic body radiation therapy (SBRT) for stage I non-small cell lung cancer (NSCLC). We queried an institution-based database on patients with SADs treated with SBRT for lung cancer between 2001 and 2016 (SAD group). Each patient was matched to three controls without SADs. The primary outcomes of interest were the overall survival (OS) and local control rate (LCR). The secondary outcomes were radiation toxicities of grades ≥2 (≥G2). Twelve patients with SADs were matched to 36 controls. The median follow-up duration was 3.6 years. There was a significant intergroup difference in the OS (hazard ratio [HR]: 4.11, 95% confidence incidence [CI]: 1.82−9.27, p < 0.001) and LCR (HR: 15.97, 95% CI: 2.89−88.29, p < 0.001). However, there were no significant intergroup differences in the odds of acute (odds ratio [OR]: 0.38, 95% CI: 0.02−8.91, p = 0.550) and late (OR: 2.20, 95% CI: 0.32−15.10, p = 0.422) ≥G2 radiation pneumonitis. No other ≥G2 toxicities were identified. In conclusion, although radiation toxicities are not enhanced by SADs, SADs are risk factors of poor prognosis following SBRT for stage I NSCLC.
Identifiants
pubmed: 36497397
pii: cancers14235915
doi: 10.3390/cancers14235915
pmc: PMC9740448
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer J. 2003 Nov-Dec;9(6):461-6
pubmed: 14740974
J Thorac Dis. 2018 Apr;10(4):2346-2356
pubmed: 29850140
Autoimmun Rev. 2003 May;2(3):119-25
pubmed: 12848952
J Thorac Dis. 2018 Mar;10(3):1158-1161
pubmed: 29708136
J Thorac Dis. 2019 Mar;11(Suppl 3):S271-S274
pubmed: 30997195
Jpn J Clin Oncol. 2013 Apr;43(4):345-50
pubmed: 23436937
J Clin Oncol. 2017 May 1;35(13):1395-1402
pubmed: 28301264
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e519-24
pubmed: 21601376
Oncotarget. 2014 Jan 30;5(2):403-16
pubmed: 24480782
JAMA Oncol. 2016 Nov 1;2(11):1507-1508
pubmed: 27262099
Radiother Oncol. 2019 Jun;135:147-152
pubmed: 31015161
Lancet Oncol. 2016 Mar;17(3):e109-e117
pubmed: 26972857
Clin Lung Cancer. 2020 Mar;21(2):136-144.e1
pubmed: 31932217
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Cancer Gene Ther. 2011 Mar;18(3):189-95
pubmed: 21052099
J Am Soc Nephrol. 2010 May;21(5):852-8
pubmed: 20431040
Front Cardiovasc Med. 2022 Jul 28;9:887705
pubmed: 35966531
Clin Cancer Res. 2006 Mar 15;12(6):1897-905
pubmed: 16551875
Radiother Oncol. 2017 Nov;125(2):293-300
pubmed: 29050957
Cancer Res. 2012 Aug 15;72(16):3967-76
pubmed: 22700877
Radiology. 2010 Jun;255(3):917-23
pubmed: 20501729
Arthritis Rheum. 2005 Feb 15;53(1):67-72
pubmed: 15696566
Cancer. 1993 Jun 1;71(11):3744-52
pubmed: 8490925
Cancer Res. 2010 Apr 1;70(7):2697-706
pubmed: 20215523
World J Radiol. 2012 Apr 28;4(4):128-34
pubmed: 22590666
Respir Med. 2008 Apr;102(4):620-4
pubmed: 18178071
Lancet. 2013 Aug 31;382(9894):819-31
pubmed: 23993191
Cancer. 2008 Aug 1;113(3):648-53
pubmed: 18506734
Food Saf (Tokyo). 2016 Jun 30;4(2):52-53
pubmed: 32231905
Autoimmun Rev. 2012 Aug;11(10):754-65
pubmed: 22387972
Cancer. 1967 Nov;20(11):1930-3
pubmed: 4168725
J Thorac Oncol. 2015 Jun;10(6):872-82
pubmed: 26001140
J Clin Oncol. 1997 Jul;15(7):2728-35
pubmed: 9215847
J Thorac Oncol. 2010 Jul;5(7):1001-10
pubmed: 20526205
Int J Radiat Oncol Biol Phys. 2021 Dec 1;111(5):1214-1226
pubmed: 34418468
Anticancer Drugs. 2006 Feb;17(2):133-8
pubmed: 16428930
Lancet Oncol. 2015 Feb;16(2):187-99
pubmed: 25601342
Radiother Oncol. 2017 Nov;125(2):301-309
pubmed: 29102264